Clinical Trials Browser

lenvatinib × CNS × 1 year × Clear all

NCT04955743 2026-06-04

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Phase 2 Terminated

18 enrolled 13 charts

CNSDermatologicGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

NCT03797326 2026-05-04

LEAP-005

Phase 2 Completed

611 enrolled 27 charts

BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05081180 2026-05-01

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Phase 1 Active not recruiting

17 enrolled

CNS

Neoplasms, Central Nervous System Neoplasms

NCT05064280 2026-04-16

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Phase 2 Recruiting

104 enrolled

CNS

Brain Neoplasms, Neoplasms

NCT07011849 2025-08-13

Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

Phase 2 Withdrawn

CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

NCT04729348 2025-07-25

Pembrolizumab And Lenvatinib In Leptomeningeal Metastases

Phase 2 Terminated

10 enrolled

CNS

Meningeal Carcinomatosis